Abnormal expression of cell cycle regulatory proteins ductal and lobular carcinomas of the breast

Modern Pathology

Volumn 13, Issue 9, 2000, Pages 945-953

  Geradts, Joseph ^a   Ingram, Christopher D ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cell cycle; Cyclin D1; Immunohistochemistry; P16; P53; Pathology

Indexed keywords

CYCLIN D1; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN P16; PROTEIN P53; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CELL CYCLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0033795449     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880172     Document Type: Article

References (39)

1. Cancer cell cycles
2. Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p55 mutations
3. Correlation of abnormalities of RB, p16(ink4a), and p53 expression with 3p loss of heterozygosity, other genetic abnormalities and clinical features in 103 primary non-small cell lung cancers
4. G1 Checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder
5. High frequency of aberrant p16(INK4A) expression in human breast cancer
6. Cyclin D1 and prognosis in human breast cancer
7. p53 Immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR-SSCP results
8. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas
9. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
10. Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas
11. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer
12. Pathological prognostic factors in breast cancer. The value of histologic grade in breast cancer: Experience from a large study with long term follow-up
13. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16(INK4A) in archival human solid tumors: Correlation with retinoblastoma protein expression
14. Immunohistochemical p16 (INK4a) analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/ MTS1 gene: A comparison of four commercial antibodies
15. Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histological parameters
16. Cell cycle-related variation and tissue-restricted expression of human cyclin D 1 protein
17. Cyclin D1 protein expression and function in human breast cancer
18. Cyclin D1 amplification and expression in human breast carcinoma: Correlation with histological prognostic markers and oestrogen receptor expression
19. Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma
20. -) infiltrating human mammary carcinomas
21. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer
22. Cyclin-D1-gene amplification and expression in breast carcinoma: Relation with clinicopathological characteristics and with retinoblastoma gene product, p53 and p21(WAF1) immunohistochemical expression
23. Cyclin D 1 expression in invasive breast cancer, correlations and prognostic value
24. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis
25. An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis
26. Expression of p53 protein has no independent prognostic value in breast cancer
27. p53 expression in breast cancer
28. p53, and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer
29. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer
30. Prognostic value of p53 in breast invasive ductal carcinoma: An immunohistochemical study on 942 cases
31. p53 gene expression in node-positive breast cancer: Relationship to DNA ploidy and prognosis
32. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis
33. p53, the cellular gatekeeper for growth and division
34. Splicing into senescence: The curious case of p16 and p19(ARF)
35. Mechanisms of p16(INK4A) inactivation in non small-cell lung cancers
36. The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53
37. 1 control
38. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein
39. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation